Jianhai Tech Secures RMB 150 Million Series B Funding Led by Sequoia China with Participation from Source Code Capital and Sherpa Capital

VCBeat (WeChat ID: vcbeat) learned of this at the earliest opportunity, on March 22, 2021, Hangzhou Jianhai Science and Technology Co., Ltd. (hereinafter referred to as “Jianhai Tech”) completed a RMB 150 million Series B financing round, led by HongShan, with participation from Source Code Capital and Sherpa Healthcare Partners. Probe Capital served as the exclusive financial advisor.。

Jianhai Technology was founded in 2015, specializing in the development and operational management of post-consultation disease management systems. It has currently partnered with over 1,000 hospitals. Upholding the philosophy of “Making Care a Potent Remedy,” Jianhai Technology is committed to advancing the construction of post-consultation disease management systems for patients, thereby enabling them to enjoy better lives and safer medical services.

This round of financing will be used to build an ecosystem for post-diagnosis disease management and service operations. Having deeply cultivated the post-diagnosis healthcare sector for many years, Hangzhou Jianhai Science and Technology Co., Ltd. has launched its “C.S.D. Three Major Series” for post-diagnosis disease management, establishing the foundational infrastructure for hospital-based post-diagnosis care. This includes the “C Series – Co-built Disease Management Services,” the “S Series – Smart Patient Service Platform,” and the “D Series – Digital Therapeutics and Research Platform.” With data as its core asset, AI to unlock industry efficiency, services to drive commercial viability, and community engagement to foster a digital therapeutics ecosystem.